Evidence map›Paper›PMID 18203439›Full record

ArticleInternational journal of nanomedicine2007

PEGylation of nanoparticles improves their cytoplasmic transport.

Junghae Suh, Kok-Leong Choy, Samuel K Lai, Jung Soo Suk, Benjamin C Tang, Sudhir Prabhu, Justin Hanes

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targeted gene therapy for cancer: the impact of microRNA multipotentiality.Medical oncology (Northwood, London, England) · 2024
    Review
  6. Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Synthesis Methodology of PEGylated FeMolecules (Basel, Switzerland) · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Promises of Nanotherapeutics in Obesity.Trends in endocrinology and metabolism: TEM · 2019
    Review
  19. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junghae SuhDepartment of Biomedical Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA.
Kok-Leong Choy
Samuel K Lai
Jung Soo Suk
Benjamin C Tang
Sudhir Prabhu
Justin Hanes

Funding

BIOMEDICAL ENGINEERING TRAINING PROGRAMT32GM007057 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI KANOLD, PATRICK O, KARCHIN, RACHEL · 1985 to 2023
$10.4M
NIGMS NIH HHS T32 GM007057NIGMS NIH HHS T32-GM07057
6 · The paper itself

Abstract

The efficacy of nucleus-targeted drug- or gene-carrying nanoparticles may be limited by slow transport through the molecularly crowded cytoplasm following endosome escape. Cytoskeletal elements and cellular organelles may pose steric and/or adhesive obstacles to the efficient intracellular transport of nanoparticles. To potentially reduce adhesive interactions of colloids with intracellular components, the surface of model nanoparticles was coated with polyethylene glycol (PEG). Subsequently, multiple-particle tracking (MPT) was used to quantify the cytoplasmic transport rates of particles microinjected into the cytoplasm of live cells. PEGylation increased average nanoparticle diffusivities by 100% compared to unPEGylated particles (time scale of 10 s) in live cells. Faster particle transport correlated with a marked decrease in the number of particles that underwent hindered transport, from 79.2% (unmodified) to 48.8% (PEGylated). This result adds to an impressive list of positive benefits associated with PEGylation of drug and gene delivery vectors.

Indexed as

Biological Transport, ActiveCytoplasmDrug CarriersDrug Delivery SystemsHeLa CellsHumansMaterials TestingNanoparticlesPolyethylene GlycolsDrug CarriersPolyethylene Glycols

Identifiers

PMID18203439
PMCPMC2676827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.